MYCN proto-oncogene, bHLH transcription factor
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The MYCN gene provides instructions for making a protein that plays an important role in the formation of tissues and organs during development before birth. Studies in animals suggest that this protein is necessary for normal development of the limbs, heart, kidneys, lungs, nervous system, and digestive system. The MYCN protein regulates the activity of other genes by attaching (binding) to specific regions of DNA and controlling the first step of protein production (transcription). On the basis of this action, this protein is called a transcription factor.
Video picks for GenesVideo library
Normal function
The MYCN gene provides instructions for making a protein that plays an important role in the formation of tissues and organs during development before birth. Studies in animals suggest that this protein is necessary for normal development of the limbs, heart, kidneys, lungs, nervous system, and digestive system. The MYCN protein regulates the activity of other genes by attaching (binding) to specific regions of DNA and controlling the first step of protein production (transcription). On the basis of this action, this protein is called a transcription factor.
The MYCN gene belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous. The MYCN gene is a member of the Myc family of oncogenes. These genes play important roles in regulating cell growth and division (proliferation) and the self-destruction of cells (apoptosis).
Conditions referring to this gene or chromosome
Other names
bHLHe37
MYCN_HUMAN
MYCNOT
N-myc
N-myc proto-oncogene protein
neuroblastoma MYC oncogene
neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene
NMYC
oncogene NMYC
pp65/67
v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived
v-myc myelocytomatosis viral related oncogene, neuroblastoma derived
v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
Patient picks for Genes

Treatment and medication
What factors are causing antimicrobial resistance?
Following a recent study by health economists at the University of Manchester and the University of Southern Denmark, the tremendous pressure GPs are currently working under has been linked to increasing broad-spectrum antibiotic prescribing in England. Because excess antibiotic prescribing has been closely linked to antibiotic resistance, there are concerns that these higher prescribing levels may be contributing to antimicrobial resistance.
by Emily Jane Bashforth

Cancer
Breast cancer facts and risk factors
Most cases of breast cancer occur by chance. However, breast cancer does occur more often than usual in some families because of their genetic makeup.
by Dr Colin Tidy, MRCGP

Treatment and medication
Proton pump inhibitors
Proton pump inhibitors reduce the amount of acid made by the stomach. They are commonly used to treat acid reflux and ulcers of the stomach and part of the gut called the duodenum. Most people who take a proton pump inhibitor do not develop any side-effects.
by Dr Philippa Vincent, MRCGP

Heart health and blood vessels
Dilated cardiomyopathy causes: what are the risk factors?
Having dilated cardiomyopathy means that your heart muscle is weakened, which affects how your heart pumps blood around your body. There are a wide range of dilated cardiomyopathy causes, including genetics, other health conditions, alcohol consumption and a poor diet. While we can't control some of these risk factors, we can make positive lifestyle changes to reduce our risk of developing dilated cardiomyopathy.
by Amberley Davis

Breast cancer types, detection and risks
What are the risk factors for breast cancer?
Dr Sarah Jarvis MBE Although breast cancer can develop for no apparent reason, there are certain risk factors which increase the chance that breast cancer will develop. [https://patient.info/health/breast-cancer-leaflet](https://patient.info/health/breast-cancer-leaflet)
by Dr Sarah Jarvis

Type 1 diabetes
Is type 1 diabetes hereditary?
Dr Partha Kar Although type 1 diabetes is not an inherited disease, there is some genetic factor. A first-degree relative (sister, brother, son, daughter) of someone with type 1 diabetes has about a 1 in 16 chance of developing type 1 diabetes. For more information on type 1 diabetes, go to [https://patient.info/health/type-1-diabetes](https://patient.info/health/type-1-diabetes)
by Dr Partha Kar, FRCP
Related patient information and medicines

Patient information leaflet
Acute lymphoblastic leukaemia
There are various subtypes of ALL. A new therapy that involves modifying a person's own immunce cells to fight the cancer has been recommended by NICE and will be available through the Cance... Kymriah, which is given as a single intravenous infusion, is a pioneering CART-cell treatment that has the potential to be a cure for people under the age.

Patient information leaflet
Neuroblastoma
Neuroblastoma is a cancer affecting developing nerve cells. Neuroblastoma is a rare cancer and most often occurs in children under 5 years old. Neuroblastoma often starts in the tummy (abdomen) but can spread to other parts of the body, especially bones, liver and skin. The treatments for neuroblastoma include surgery... Genetic changes. Some.

Patient information leaflet
Causes of cancer
Certain risk factors are known to increase the chance that one or more of your cells will become abnormal and lead to cancer. How does cancer start. The body is made up from millions of tiny cells. Different parts of the body such as organs, bones, muscles, skin and blood are made up from different specialised cells. Most cells have a centre.

Patient information leaflet
Mouth cancer
Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore, an ulcer or a lump) which has not healed for 3 wee... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or.

Patient information leaflet
Throat cancer
(The throat is usually sprayed with a local anaesthetic before use of a nasal endoscope, so that the procedure i... Dr Krishna Vakharia, 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their.

Patient information leaflet
Blood clotting tests
Blood clotting tests are used to diagnose and assess bleeding problems and to monitor people who take warfarin or other anticoagulant medicines. You may be advised to have blood clotting tests: If you have a suspected bleeding disorder. For example, if you bleed a lot after cuts, or if you bruise easily. If you have certain liver diseases that can.
Further reading and references
- MYCN proto-oncogene, bHLH transcription factor; MedlinePlus, National Library of Medicine.
- Albertson DG. Gene amplification in cancer. Trends Genet. 2006 Aug;22(8):447-55. doi: 10.1016/j.tig.2006.06.007. Epub 2006 Jun 19.
- Ewens KG, Bhatti TR, Moran KA, Richards-Yutz J, Shields CL, Eagle RC, Ganguly A. Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma. Cancer Med. 2017 Mar;6(3):619-630. doi: 10.1002/cam4.1010. Epub 2017 Feb 17.
- Jacobs JF, van Bokhoven H, van Leeuwen FN, Hulsbergen-van de Kaa CA, de Vries IJ, Adema GJ, Hoogerbrugge PM, de Brouwer AP. Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer. 2009 Jul 18;9:239. doi: 10.1186/1471-2407-9-239.
- Marcelis CL, Hol FA, Graham GE, Rieu PN, Kellermayer R, Meijer RP, Lugtenberg D, Scheffer H, van Bokhoven H, Brunner HG, de Brouwer AP. Genotype-phenotype correlations in MYCN-related Feingold syndrome. Hum Mutat. 2008 Sep;29(9):1125-32. doi: 10.1002/humu.20750.
- Marcelis CLM, de Brouwer APM. Feingold Syndrome 1. 2009 Jun 30 [updated 2019 Apr 4]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK7050/
- Mirzamohammadi F, Kozlova A, Papaioannou G, Paltrinieri E, Ayturk UM, Kobayashi T. Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. Nat Commun. 2018 Apr 10;9(1):1352. doi: 10.1038/s41467-018-03788-7.
- Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983 Sep 15-21;305(5931):245-8. doi: 10.1038/305245a0.
- Soliman SE, Racher H, Zhang C, MacDonald H, Gallie BL. Genetics and Molecular Diagnostics in Retinoblastoma--An Update. Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):197-207. doi: 10.22608/APO.201711.
- Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res. 2006 Mar 1;66(5):2826-33. doi: 10.1158/0008-5472.CAN-05-0854.
- van Bokhoven H, Celli J, van Reeuwijk J, Rinne T, Glaudemans B, van Beusekom E, Rieu P, Newbury-Ecob RA, Chiang C, Brunner HG. MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. Nat Genet. 2005 May;37(5):465-7. doi: 10.1038/ng1546. Epub 2005 Apr 10.
- Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P, Vermeulen J, Vandesompele J, Speleman F. The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med. 2009 Jul 27;1(7):74. doi: 10.1186/gm74.
- Vasudevan SA, Nuchtern JG, Shohet JM. Gene profiling of high risk neuroblastoma. World J Surg. 2005 Mar;29(3):317-24. doi: 10.1007/s00268-004-7820-7.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

